Trop-2 mRNA Expression and Association with Clinical Outcomes with Sacituzumab Govitecan (SG) in Patients with HR+/HER2– Metastatic Breast Cancer (mBC): Biomarker Results from the Phase 3 TROPiCS-02 StudyĪSCENT-05/Optimice-RD (AFT-65): Phase 3, Randomized, Open-Label Study of Adjuvant Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) vs. ![]() ARC-7 is an approximately 150-patient randomized Phase 2 study evaluating domvanalimab plus anti-PD-1 antibody zimberelimab (doublet) and domvanalimab plus zimberelimab and etrumadenant, an A2a/b adenosine receptor antagonist (triplet), versus zimberelimab alone.įurther highlighting progress being made across Gilead’s oncology pipeline, trial updates will be shared from ongoing studies in lung cancer, triple-negative breast cancer, UC and several other solid tumors.Īccepted abstracts at the 2023 ASCO Annual Meeting include (all times CDT):įinal Overall Survival (OS) Analysis from the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) in Patients (Pts) with Hormone Receptor–Positive/HER2-Negative (HR+/HER2–) Metastatic Breast Cancer (mBC) This includes an oral presentation with our partner Arcus Biosciences, on the updated interim analysis of ARC-7, which will detail updated efficacy and safety results for domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, in first-line NSCLC with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations. Gilead Highlights Emerging Lung Cancer Pipeline, Progress in Solid Tumorsīeyond our ongoing late-stage development program evaluating the investigational use of Trodelvy in non-small cell lung cancer (NSCLC), Gilead will highlight clinical data and trial updates from several other lung cancer trials. ![]() “We are particularly excited to share our overall survival data from the pivotal ZUMA-7 study for Yescarta for initial treatment of relapsed/refractory large B-cell lymphoma, the first and only treatment in 30 years to demonstrate a statistically significant improvement in overall survival versus historical standard of care in this patient population.” “The data that will be presented at ASCO represent another significant step forward in our goal of bringing the hope of survival to more patients through our innovative cell therapies,” said Frank Neumann, MD, PhD, SVP, Kite’s Global Head of Clinical Development. Further analysis of the pivotal ZUMA-3 study in adult B-cell acute lymphoblastic leukemia, in addition to real-world evidence in follicular lymphoma and mantle cell lymphoma, will also be presented. Kite Therapies Continue to Advance the Standard of Care in Leukemia and LymphomaĪ late-breaking oral presentation from the landmark Phase 3 ZUMA-7 study will highlight OS results for Yescarta ® (axicabtagene ciloleucel) versus standard of care for initial treatment of adult patients with relapsed/refractory large B-cell lymphoma (LBCL) within 12 months of completion of first-line therapy. Additionally, Gilead will present the first Phase 2 data evaluating Trodelvy as a potential therapy in advanced endometrial cancer. Gilead will also share data evaluating Trodelvy in metastatic urothelial cancer (UC) in the U.S., Trodelvy currently has an accelerated approval for the treatment of certain patients with second-line metastatic UC. New Data Reinforce Pan-Tumor Efficacy of Trodelvy ®įinal overall survival (OS) results from the Phase 3 TROPiCS-02 study for Trodelvy ® (sacituzumab govitecan-hziy) in HR+/HER2- metastatic breast cancer (mBC) will be presented in an oral session. “We are determined to deliver the best outcomes for patients and are proud to highlight the pan-tumor efficacy of Trodelvy as well as our growing presence across lung cancer and many other tumor types.” ![]() “The breadth of data being presented at ASCO is a testament to our commitment in helping to bring more life to people with cancer,” said Bill Grossman, MD, PhD, Senior Vice President, Therapeutic Area Head, Gilead Oncology. These data reinforce the strength of Gilead and Kite Oncology’s transformative science in hard-to-treat cancers. (Nasdaq: GILD) and Kite, a Gilead Company, will present 30 abstracts during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. – Updated Interim Results from Phase 2 ARC-7 Study of Fc-Silent Anti-TIGIT Monoclonal Antibody Domvanalimab to be Featured in Oral Presentation –įOSTER CITY, Calif. – Late-Breaking Presentation to Detail Overall Survival Results for Yescarta ® CAR T-Cell Therapy, Showing Statistical Improvement Over Standard of Care for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma – ![]() – Data Across 30 Abstracts Reinforce Leadership in Metastatic Breast Cancer and Demonstrate Breadth of Pipeline Across Lung, Hematologic, Genitourinary, Gastrointestinal, Gynecological and Other Solid Tumors –
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |